Earnings summaries and quarterly performance for CytomX Therapeutics.
Executive leadership at CytomX Therapeutics.
Board of directors at CytomX Therapeutics.
Research analysts who have asked questions during CytomX Therapeutics earnings calls.
Mitchell Kapoor
H.C. Wainwright & Co.
5 questions for CTMX
Also covers: HALO, INM, IONS +7 more
PL
Peter Lawson
Barclays PLC
4 questions for CTMX
Also covers: ADAP, ARVN, BPMC +15 more
AR
Anupam Rama
JPMorgan Chase & Co.
3 questions for CTMX
Also covers: APLS, BBIO, BOLD +16 more
ET
Edward Tenthoff
Piper Sandler Companies
2 questions for CTMX
Also covers: ARVN, ARWR, CAPR +14 more
Matthew Biegler
Oppenheimer & Co. Inc.
2 questions for CTMX
Also covers: ALLO, ARVN, FULC +2 more
Nabeel Nissar
Jefferies
2 questions for CTMX
D(
Dan (on for Mitchell Kapoor)
H.C. Wainright
1 question for CTMX
ED
Etzer Darout
BMO Capital Markets
1 question for CTMX
Also covers: ARVN, EXEL, GMAB +5 more
J
Jeff
B. Riley
1 question for CTMX
Also covers: NIO
JS
Jiale Song
Jefferies Financial Group Inc.
1 question for CTMX
Also covers: ACRS, CRVS, CVAC +12 more
Joe Catanzaro
Piper Sandler
1 question for CTMX
Also covers: AADI, CNTB, IMAB +1 more
JC
Joseph Catanzaro
Wolfe Research, LLC
1 question for CTMX
Also covers: AADI, CPRX, CRDF +7 more
Liang Cheng
Jefferies
1 question for CTMX
Also covers: AADI, INO, VXRT
RD
Robert Driscoll
Wedbush Securities
1 question for CTMX
Also covers: CMPX
Recent press releases and 8-K filings for CTMX.
CytomX Provides Clinical Development Update for Vaseta M and CX801 at J.P. Morgan Healthcare Conference
CTMX
New Projects/Investments
Guidance Update
- CytomX is expanding its Phase 1 study for Vaseta M, an EpCAM-targeting Topo-1 ADC for colorectal cancer, to over 100 patients and anticipates a data update by the end of Q1 2026.
- Initial Vaseta M data from May 2025 demonstrated a 28% confirmed overall response rate (ORR) and 5.8 months of preliminary progression-free survival (PFS) in late-line metastatic CRC, targeting a US market opportunity of over $5 billion in the third-line setting alone.
- The company is also progressing CX801, a Probody version of interferon alpha-2b for melanoma, with the goal of achieving proof of concept by the end of 2026 in combination with Keytruda, with initial combination data expected by year-end.
- CytomX maintains a robust cash position, providing funding well into Q2 2027, excluding potential milestones or new business development.
Jan 14, 2026, 5:00 PM
CytomX Provides Clinical Program Updates and Financial Outlook at J.P. Morgan Healthcare Conference
CTMX
New Projects/Investments
Guidance Update
- CytomX, an oncology-focused biotech company, is advancing two clinical programs: Vaseta M (EpCAM-targeting ADC for colorectal cancer) and CX801 (Probody interferon alpha-2b for melanoma).
- For Vaseta M, the Phase 1 study is expanding to over 100 patients, with a data update expected by the end of Q1 2026. Previous data from May 2025 showed a 28% confirmed overall response rate in late-line colorectal cancer.
- The company aims to achieve proof of concept for CX801 in combination with Keytruda by the end of 2026, with initial combination data anticipated by that time.
- CytomX reports a robust cash position, providing funding well into Q2 2027, excluding potential milestones or new business development.
Jan 14, 2026, 5:00 PM
CytomX Provides Updates on Vaseta M and CX801 Clinical Programs
CTMX
New Projects/Investments
Guidance Update
- CytomX is expanding its Phase 1 study for Vaseta M, an EpCAM-targeting Topo-1 ADC for colorectal cancer, to more than 100 patients and anticipates a data update by the end of Q1 2026.
- The company previously reported a 28% confirmed overall response rate and 5.8 months of preliminary progression-free survival for Vaseta M in late-line colorectal cancer patients.
- CytomX aims to achieve proof of concept for CX801, a Probody version of interferon alpha-2b for melanoma, in combination with Keytruda by the end of 2026.
- The company maintains a robust cash position, providing a financial runway well into Q2 2027, excluding potential milestones or new business development.
Jan 14, 2026, 5:00 PM
CytomX Provides Updates on PROBODY® Platform and Clinical Programs
CTMX
New Projects/Investments
Guidance Update
- CytomX is advancing its PROBODY® Platform with key clinical programs, Varsetatug masetecan (Varseta-M) for colorectal cancer and CX-801 for melanoma.
- Varseta-M (EpCAM PROBODY® Topo-1 ADC) demonstrated encouraging interim Phase 1 clinical data in late-line metastatic CRC (data cutoff April 7, 2025), showing a 28% confirmed overall response rate (ORR) and 94% disease control. Phase 1 expansion data is expected in Q1 2026.
- The company anticipates releasing Phase 1 data for CX-801 in combination with KEYTRUDA® for advanced melanoma by 2026 Year-End.
- CytomX has a cash runway extending to Q2 2027, excluding any potential milestones or new business development, and maintains partnerships with Bristol Myers Squibb, Amgen, Astellas, Regeneron, and Moderna.
Jan 14, 2026, 5:00 PM
CytomX Highlights Positive Clinical Data for CX-2051 and CX-801, Reports Strong Financial Position
CTMX
Guidance Update
New Projects/Investments
- CytomX reported encouraging Phase 1 data for CX-2051 in metastatic colorectal cancer, demonstrating a 28% confirmed response rate and 5.8 months progression-free survival in late-stage patients. The company aims for a registrational path as monotherapy, with an update expected in Q1 2026 and a bevacizumab combination study initiating in Q1 2026.
- Early Phase 1 data for CX-801 in melanoma showed the drug's mechanism is working as designed, activating interferon-responsive genes and recruiting T cells. A combination study with Keytruda is ongoing, with data anticipated in late 2026.
- The company is in a robust financial position, with $144 million in cash at the end of Q3 (subsequently $150-$158 million with ATM), providing funding into Q2 2027. This enables continued clinical development for both CX-2051 and CX-801.
- The positive clinical data for CX-2051 has validated CytomX's Probody platform, and the company remains open to additional platform partnerships.
Dec 4, 2025, 6:00 PM
CytomX Discusses Clinical Pipeline and Financial Outlook at Piper Sandler Conference
CTMX
Product Launch
New Projects/Investments
Guidance Update
- CytomX reported encouraging Phase 1 data for its masked anti-EpCAM ADC, CX-2051, in metastatic colorectal cancer, showing a 28% confirmed response rate and 5.8 months progression-free survival in late-line patients. The company plans to provide an update in Q1 next year and aims for a registrational path as monotherapy, with a combination study with bevacizumab initiating in Q1 next year.
- Early Phase 1 data for CX-801, a masked interferon alpha-2b, in melanoma demonstrated compelling biomarker data, including activation of interferon responsive genes and recruitment of CD8 positive T cells into the tumor microenvironment. A combination study with Keytruda began earlier this year, with data expected in late 2026.
- CytomX ended Q3 with $144 million in cash, providing funding into Q2 2027, which supports ongoing clinical studies for CX-2051 and CX-801.
- The company is open for additional platform partnerships on the discovery side, leveraging its Probody platform.
Dec 4, 2025, 6:00 PM
CytomX Provides Updates on Clinical Pipeline and Financial Outlook
CTMX
New Projects/Investments
Guidance Update
- CytomX reported encouraging Phase 1 data for CX-2051 (EpCAM ADC) in metastatic colorectal cancer in May 2025, demonstrating a 28% confirmed response rate and 5.8 months progression-free survival in late-stage patients. An update on the expanded Phase 1 study is anticipated in Q1 2026.
- Early Phase 1 data for CX-801 (masked interferon alpha-2b) in melanoma, presented at SITC, showed activation of interferon responsive genes and recruitment of CD8 positive T cells into the tumor microenvironment. Combination therapy with Keytruda began in 2025, with data expected in late 2026.
- The company concluded Q3 2025 with $144 million in cash, which is expected to fund operations into Q2 2027.
Dec 4, 2025, 6:00 PM
CytomX Provides Update on CX2051 Colorectal Cancer Data and CX-801 Program
CTMX
New Projects/Investments
Guidance Update
- CytomX (CTMX) is developing CX2051, a masked antibody-drug conjugate (ADC) targeting EpCAM for colorectal cancer (CRC).
- Initial Phase 1 dose escalation data for CX2051 in late-stage CRC patients (median of four prior therapies) showed a 28% confirmed response rate in 18 efficacy-evaluable patients, 94% disease control, and 5.8 months of progression-free survival (PFS).
- The Phase 1 study for CX2051 is expanding to 100 patients, with the next data update anticipated in Q1 2026.
- CytomX is also developing CX-801, a masked interferon alpha-2b, with preliminary data showing activation of interferon signaling in tumors. A combination study of CX-801 with Keytruda is underway, with data expected in late-stage melanoma in 2026.
Dec 2, 2025, 6:45 PM
CytomX Updates on CX-2051 Colorectal Cancer Data and CX-801 Development
CTMX
New Projects/Investments
- CytomX's lead asset, CX-2051, an EpCAM-targeting antibody-drug conjugate (ADC), demonstrated a 28% confirmed response rate and 5.8 months progression-free survival in initial Phase 1 data from 18 efficacy evaluable late-stage colorectal cancer patients.
- The Phase 1 study for CX-2051 is expanding enrollment to 100 patients, with the next data update planned for Q1 2026.
- CytomX intends to initiate a Bev combination Phase Ib study for CX-2051 in Q1 2026 and explore non-colorectal cancer indications in 2026.
- The company is also developing CX-801, a masked interferon alpha-2b, with combination data with Keytruda in late-stage melanoma expected by the end of 2026.
Dec 2, 2025, 6:45 PM
CytomX Therapeutics Highlights Promising CX-2051 Phase 1 Data and Q1 2026 Data Disclosure
CTMX
New Projects/Investments
Guidance Update
- CytomX Therapeutics reported promising Phase 1 data for its EpCAM ADC program, CX-2051, in May 2025, demonstrating a 28% confirmed overall response rate and 5.8 months preliminary progression-free survival in late-stage colorectal cancer patients, significantly exceeding the 1-2% response rates and ~3 months PFS of current standard of care.
- The company plans to disclose additional data for CX-2051 in Q1 2026, with enrollment expanded to approximately 100 patients to confirm efficacy, further assess safety, and determine optimal dosing for future studies.
- CytomX is actively addressing a 21% Grade 3 diarrhea signal observed with CX-2051 by implementing prophylactic loperamide, with updates on mitigation strategies expected in the Q1 2026 data release.
- The company reported a strong financial position with cash of just under $150 million, which is expected to fund operations into Q2 2027.
Nov 20, 2025, 1:00 PM
Quarterly earnings call transcripts for CytomX Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more